Iovance announced that first patient has been dosed in Cohort 4, the pivotal cohort of the innovaTIL-01 study of lifileucel. Cohort 4 is designed to enroll 75 patients with advanced melanoma. InnovaTIL-01 is a pivotal phase 2 global multicenter study evaluating the safety and efficacy of Iovance’s autologous lifileucel TIL therapy for treatment of patients with metastatic melanoma.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.